FERMT2 and prostate carcinoma: In esophageal squamous cell carcinoma cells, kindlin-2/β1 integrin/AKT signaling activation promotes tumor invasion13; in prostate cancer cell lines, inhibition of the kindlin-2/β1 integrin pathway enhances the sensitivity to chemotherapeutic agents14.